Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Glucagon-like peptide 1 treatment reverses vascular remodelling by downregulating matrix metalloproteinase 1 expression through inhibition of the ERK1/2/NF-κB signalling pathway
Shaohua Fan, Qianfeng Xiong, Lei Wang, et al.
Molecular and Cellular Endocrinology (2020) Vol. 518, pp. 111005-111005
Closed Access | Times Cited: 21

Showing 21 citing articles:

GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential
Xiaoxuan Ma, Zhenghong Liu, Iqra Ilyas, et al.
International Journal of Biological Sciences (2021) Vol. 17, Iss. 8, pp. 2050-2068
Open Access | Times Cited: 152
The blood pressure lowering effects of glucagon-like peptide-1 receptor agonists: A mini-review of the potential mechanisms
João Carlos Ribeiro-Silva, Caio A.M. Tavares, Adriana Castello Costa Girardi
Current Opinion in Pharmacology (2023) Vol. 69, pp. 102355-102355
Closed Access | Times Cited: 30
Network Pharmacology and Molecular Docking-Based Mechanism Study to Reveal the Protective Effect of Salvianolic Acid C in a Rat Model of Ischemic Stroke
Yuting Yang, Yu He, Xiaoyu Wei, et al.
Frontiers in Pharmacology (2022) Vol. 12
Open Access | Times Cited: 27
Application of glucagon-like peptide-1 receptor antagonists in fibrotic diseases
Fuxun Yang, Xiaoxiu Luo, Jiajia Li, et al.
Biomedicine & Pharmacotherapy (2022) Vol. 152, pp. 113236-113236
Open Access | Times Cited: 17
Biology and Clinical Use of Glucagon-Like Peptide-1 Receptor Agonists in Vascular Protection
Kevin Yau, Ayodele Odutayo, Satya Dash, et al.
Canadian Journal of Cardiology (2023) Vol. 39, Iss. 12, pp. 1816-1838
Closed Access | Times Cited: 7
Glucose control independent mechanisms involved in the cardiovascular benefits of glucagon-like peptide-1 receptor agonists
Qinchao Wu, Daisong Li, Chao Huang, et al.
Biomedicine & Pharmacotherapy (2022) Vol. 153, pp. 113517-113517
Open Access | Times Cited: 12
DPP‐4 inhibitor sitagliptin treatment results in altered myocardial metabolic proteome and oxidative phosphorylation in a swine model of chronic myocardial ischemia
Dwight D. Harris, Sharif A. Sabe, Mark Broadwin, et al.
Physiological Reports (2024) Vol. 12, Iss. 5
Open Access | Times Cited: 2
The Effects of Glucagon-Like Peptide-1 Receptor Agonists and Dipeptydilpeptidase-4 Inhibitors on Blood Pressure and Cardiovascular Complications in Diabetes
Habib Yaribeygi, Farin Rashid Farokhi, Mohammed Abdalla, et al.
Journal of Diabetes Research (2021) Vol. 2021, pp. 1-10
Open Access | Times Cited: 15
Omarigliptin Protects the Integrity of the Blood–Brain Barrier After Intracerebral Hemorrhage in Mice
Yan Zhang, Yang Liu, Xiangyu Zhang, et al.
Journal of Inflammation Research (2023) Vol. Volume 16, pp. 2535-2548
Open Access | Times Cited: 6
Cardiovascular protection by DPP-4 inhibitors in preclinical studies: an updated review of molecular mechanisms
Esraa M. Zakaria, Walaa M. Tawfeek, Mohamed H. Hassanin, et al.
Naunyn-Schmiedeberg s Archives of Pharmacology (2022) Vol. 395, Iss. 11, pp. 1357-1372
Open Access | Times Cited: 8
Study on Optimal Extraction and Hypoglycemic Effect of Quercetin
Lei Zhang, Mingyue Pan, Tao Li, et al.
Evidence-based Complementary and Alternative Medicine (2023) Vol. 2023, Iss. 1
Open Access | Times Cited: 4
Glucagon-like peptide-1 receptor agonists: new strategies and therapeutic targets to treat atherosclerotic cardiovascular disease
Tianyu Wang, Juncan Ding, Xinyi Cheng, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 1
Cardiovascular effects of GLP-1 receptor agonism
Raymond J. Winquist, Valentin K. Gribkoff
Advances in pharmacology (2022), pp. 213-254
Closed Access | Times Cited: 6
Potential Role of GLP-1 Based Therapeutics in Coronary Artery Disease
Qianfeng Xiong, Jing Wang, Kewen Huang, et al.
Frontiers in Bioscience-Landmark (2023) Vol. 28, Iss. 11
Open Access | Times Cited: 2
Endogenous Vasoactive Peptides and Vascular Aging-Related Diseases
Yao Chen, Yongfen Qi, Weiwei Lu
Oxidative Medicine and Cellular Longevity (2022) Vol. 2022, pp. 1-22
Open Access | Times Cited: 4
Liraglutide reduces coronary endothelial cells no-reflow damage through activating MAPK/ERK signaling pathway
Yi Chen, Chen Liu, Peng Zhou, et al.
Journal of Receptors and Signal Transduction (2020) Vol. 41, Iss. 6, pp. 553-557
Closed Access | Times Cited: 5
The role of glucagon-like peptide-1 receptor agonists (GLP1-RAs) in the management of the hypertensive patient with metabolic syndrome: a position paper from the Korean society of hypertension
Hae‐Young Lee, Seung‐Hyun Ko, Sungjoon Park, et al.
Clinical Hypertension (2024) Vol. 30, Iss. 1
Open Access
Rapid Gastric emptying in spontaneously hypertensive rats
Umber A. Salman, Joyce G. Schwartz, Alex McMahan, et al.
Journal of Hypertension (2023) Vol. 42, Iss. 3, pp. 572-578
Closed Access | Times Cited: 1
A GLP-1-receptoragonista liraglutid direkt hatásai az érfali diszfunkcióra 2-es típusú cukorbetegségben
Ferenc Sztanek, Attila Pető
Diabetologia Hungarica (2022) Vol. 30, Iss. 5, pp. 359-368
Open Access | Times Cited: 1
The Key Role of Liraglutide in Preventing Autophagy of Vascular Smooth Muscle Cells in High Glucose Conditions
Lili Shi, Ming Hao, Guangjing Qu, et al.
Balkan Medical Journal (2023), pp. 54-63
Open Access
Expression profile of lncRNA induced by DPP4 in human aortic smooth muscle cells and calcification gene prediction
Tongjie Xu, Hao Chen, Xiongfei Xu, et al.
Research Square (Research Square) (2022)
Open Access
Page 1

Scroll to top